.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,362,178

« Back to Dashboard
Patent 6,362,178 protects LEVITRA and STAXYN and is included in two NDAs. There have been zero Paragraph IV challenges on Staxyn and Levitra There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has eighty-four patent family members in forty-six countries.

Summary for Patent: 6,362,178

Title: 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/554,162
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 65th percentile
Forward Citations: 18th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
LEVITRA
vardenafil hydrochloride
TABLET;ORAL021400-003Aug 19, 2003RXNo6,362,178► subscribeYY ERECTILE DYSFUNCTION
Bayer Hlthcare
LEVITRA
vardenafil hydrochloride
TABLET;ORAL021400-001Aug 19, 2003RXNo6,362,178► subscribeYY ERECTILE DYSFUNCTION
Bayer Hlthcare
LEVITRA
vardenafil hydrochloride
TABLET;ORAL021400-002Aug 19, 2003RXNo6,362,178► subscribeYY ERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,362,178

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998
PCT Information
PCT FiledOctober 31, 1998PCT Application Number:PCT/EP98/06910
PCT Publication Date:May 20, 1999PCT Publication Number: WO99/24433

Non-Orange Book Patents for Patent: 6,362,178

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► subscribe
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► subscribe
7,122,5402-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,362,178

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina013759► subscribe
Argentina035972► subscribe
Austria213246► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc